

# William R Macon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9186765/publications.pdf>

Version: 2024-02-01

77  
papers

2,584  
citations

361296  
20  
h-index

189801  
50  
g-index

79  
all docs

79  
docs citations

79  
times ranked

3405  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Histiocyte-rich pseudotumor " a post-chemotherapy radiologic dilemma. <i>Journal of Hematopathology</i> , 2022, 15, 45.  | 0.2 | 0         |
| 2  | PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.   | 2.8 | 1         |
| 3  | Academic boycotts of Russian science: where does the <i>Journal of Hematopathology</i> stand?. <i>Journal of Hematopathology</i> , 2022, 15, 49-49.  | 0.2 | 2         |
| 4  | Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.  | 3.3 | 28        |
| 5  | Cutaneous ALK-positive histiocytosis. <i>Journal of Hematopathology</i> , 2021, 14, 89-91.   | 0.2 | 2         |
| 6  | A radiology survey and sub-sub-specialization in hematopathology. <i>Journal of Hematopathology</i> , 2021, 14, 1-2.   | 0.2 | 0         |
| 7  | Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021, 149, 535-545.   | 2.3 | 4         |
| 8  | SARS-CoV-2/COVID-19 pandemic produces a new paradigm for international hematopathology meetings. <i>Journal of Hematopathology</i> , 2021, 14, 95-95.  | 0.2 | 0         |
| 9  | Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.   | 2.8 | 4         |
| 10 | What, how, and when for the WHO: will the clock be turned back for the next hematolymphoid tumor classification?. <i>Journal of Hematopathology</i> , 2021, 14, 185-186.   | 0.2 | 3         |
| 11 | Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. <i>HemaSphere</i> , 2021, 5, e640.  | 1.2 | 7         |
| 12 | Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. <i>Blood Cancer Journal</i> , 2021, 11, 160. | 2.8 | 3         |
| 13 | PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.  | 0.6 | 0         |
| 14 | Bone involvement on PET/CT predicts event-free survival in follicular lymphoma Grade 3B. <i>British Journal of Haematology</i> , 2020, 191, e41-e43.   | 1.2 | 2         |
| 15 | Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.   | 0.6 | 14        |
| 16 | Assessing for disease: recurrent mycosis fungoides or cutaneous granulomatous drug eruption after mogamulizumab therapy. <i>Journal of Hematopathology</i> , 2020, 13, 287-288.  | 0.2 | 0         |
| 17 | Computational histopathology and deep transfer learning: characterizing the molecular basis of tumor morphology. <i>Journal of Hematopathology</i> , 2020, 13, 203-204.  | 0.2 | 1         |
| 18 | Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2274-2276.   | 0.6 | 4         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | COVID-19 and remembering Professor Dennis H. Wright. <i>Journal of Hematopathology</i> , 2020, 13, 77-78.  | 0.2 | 1         |
| 20 | Twenty years later: has cell of origin testing in diffuse large B cell lymphoma run its course?. <i>Journal of Hematopathology</i> , 2020, 13, 1-3.  | 0.2 | 2         |
| 21 | Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. <i>Oncologist</i> , 2020, 25, 689-695.   | 1.9 | 7         |
| 22 | Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.  | 0.6 | 2         |
| 23 | Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. <i>Blood</i> , 2020, 136, 47-48.  | 0.6 | 0         |
| 24 | Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. <i>Blood</i> , 2020, 136, 15-16.   | 0.6 | 0         |
| 25 | SOLAHP: a fledgling organization rapidly taking flight. <i>Journal of Hematopathology</i> , 2019, 12, 107-107.   | 0.2 | 0         |
| 26 | Desmoplastic Infantile Ganglioglioma: A MAPK Pathway-Driven and Microglia/Macrophage-Rich Neuroepithelial Tumor. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 1011-1021.  | 0.9 | 21        |
| 27 | Advancing diagnostic hematopathology: pigeons or pixels?. <i>Journal of Hematopathology</i> , 2019, 12, 49-50.   | 0.2 | 0         |
| 28 | Elucidating a false-negative <i>MYC</i> break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with <i>IGH/MYC</i> and <i>IGH/BCL2</i> rearrangements. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004077. | 0.5 | 14        |
| 29 | Keeping tabs on the mabs: a hematopathologist's dilemma. <i>Journal of Hematopathology</i> , 2019, 12, 1-2.  | 0.2 | 0         |
| 30 | Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 786-793.   | 2.0 | 15        |
| 31 | Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.   | 0.6 | 4         |
| 32 | Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.  | 0.6 | 0         |
| 33 | High-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , 2018, 131, 2060-2064.   | 0.6 | 167       |
| 34 | Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.  | 1.2 | 5         |
| 35 | Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1647-1652.   | 2.1 | 23        |
| 36 | CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.   | 2.8 | 22        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.   | 0.8 | 13        |
| 38 | Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.                          | 1.7 | 52        |
| 39 | An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. <i>Blood</i> , 2018, 132, 2247-2247.   | 0.6 | 2         |
| 40 | Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2018, 132, 456-456.    | 0.6 | 4         |
| 41 | Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018, 132, 4204-4204.                   | 0.6 | 1         |
| 42 | High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962. | 0.6 | 1         |
| 43 | Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018. <i>Blood</i> , 2018, 132, 574-574.  | 0.6 | 0         |
| 44 | Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2018, 132, 2979-2979.   | 0.6 | 0         |
| 45 | Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. <i>Human Pathology</i> , 2017, 64, 19-27.  | 1.1 | 41        |
| 46 | Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 448-453.  | 2.0 | 26        |
| 47 | Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 427-433.                      | 1.2 | 15        |
| 48 | Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.  | 0.9 | 57        |
| 49 | Clinical heterogeneity of diffuse large B cell lymphoma following failure of frontline immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.  | 1.2 | 49        |
| 50 | Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.  | 2.0 | 41        |
| 51 | Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.  | 2.0 | 180       |
| 52 | Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.   | 0.6 | 1         |
| 53 | Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016, 128, 155-155.  | 0.6 | 1         |
| 54 | Prognostic Impact of Morphology, <i>MYC</i> Gene Partner and <i>BCL2/BCL6</i> Translocation Status in "High Grade B-Cell Lymphomas with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements". <i>Blood</i> , 2016, 128, 1750-1750.       | 0.6 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. <i>Blood</i> , 2016, 128, 3033-3033.   | 0.6 | 2         |
| 56 | Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.   | 0.6 | 5         |
| 57 | Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.   | 0.6 | 5         |
| 58 | Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.  | 0.6 | 1         |
| 59 | Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016, 128, 3036-3036.  | 0.6 | 0         |
| 60 | Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. <i>Blood</i> , 2016, 128, 5322-5322.   | 0.6 | 0         |
| 61 | Neurolymphomatosis: A report of 2 cases representing opposite ends of the clinical spectrum. <i>Muscle and Nerve</i> , 2015, 52, 449-454.   | 1.0 | 9         |
| 62 | Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Center and Cancer Research and Biostatistics from 1998 to 2011. <i>American Journal of Hematology</i> , 2015, 90, 790-795. | 2.0 | 221       |
| 63 | The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.  | 0.6 | 92        |
| 64 | Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2683-2683.   | 0.6 | 6         |
| 65 | ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.  | 0.6 | 401       |
| 66 | IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013, 122, 362-362.  | 0.6 | 2         |
| 67 | Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. <i>Blood</i> , 2013, 122, 4179-4179.   | 0.6 | 4         |
| 68 | Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.  | 0.8 | 70        |
| 69 | Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.   | 0.8 | 184       |
| 70 | Peripheral T-Cell Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 829-842.   | 0.9 | 16        |
| 71 | MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras. <i>Blood</i> , 2009, 114, 443-443.   | 0.6 | 0         |
| 72 | Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. <i>Modern Pathology</i> , 2008, 21, 455-463.   | 2.9 | 195       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Incidence of TCR and TCL1 Gene Translocations and Isochromosome 7q in Peripheral T-Cell Lymphomas Using Fluorescence In Situ Hybridization. American Journal of Clinical Pathology, 2008, 130, 178-185.                           | 0.4 | 45        |
| 74 | Syk Tyrosine Kinase Is Overexpressed in the Majority of Peripheral T- and NK-Cell Lymphomas, and Represents a Potential Therapeutic Target.. Blood, 2007, 110, 690-690.   | 0.6 | 3         |
| 75 | Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?. Blood, 2005, 106, 1501-1502.   | 0.6 | 161       |
| 76 | Hepatosplenic CD45 <sup>RO</sup> T-Cell Lymphomas. American Journal of Surgical Pathology, 2001, 25, 285-296.   | 2.1 | 214       |
| 77 | Hepatosplenic and Subcutaneous Panniculitis-Like CD45 <sup>RO</sup> T Cell Lymphomas Are Derived from Different CD45 <sup>RO</sup> Subsets of CD45 <sup>RO</sup> T Lymphocytes. Journal of Molecular Diagnostics, 2000, 2, 11-19. | 1.2 | 104       |